NanoViro: Nanotechnology Virus for safer research & drug development
Advantages
- Mimics virus size and surface features for accurate studies.
- Replaces live viruses, avoiding high-containment lab requirements.
- Drug testing for permeability and viral prevention.
- Safety (reduce risks of exposure to dangerous pathogens).
- Scalable, cost-effective virology research solutions.
Goal
The group is looking for a license agreement, but other collaborations may be considered.
Patent
Patent Application Number: PCT/EP2024/070497
Priority date: July 19, 2024
Reference
UBTT0476-E-b
Contact
Vicenç Gómez
Email: vgomez@fbg.ub.ed
Inma Íñiguez
Email: iiniguez@fbg.ub.ed
NanoViro: Nanotechnology Virus for safer research & drug development
Executive summary
A research group, with wide experience on micro-and nanostructured functional materials, has generated a “virus model nanoparticle”.
The group is looking for a license, but other collaborations may be considered.
Introduction
Respiratory viruses, like those from the Coronaviridae family, pose a global health threat due to their rapid mutations and high transmissibility. Traditional virology research is costly, risky, and requires specialized high-containment laboratories. To accelerate drug discovery and antiviral development, a safer, scalable, and efficient alternative is urgently needed.
Description
NanoViro is an advanced virus model nanoparticle that emulates the size, shape and surface characteristics of viruses. With a metal core coated in a specialized organic layer, this nanoparticle provides a safe, reliable and cost-effective solution for virology research. NanoViro model enables the study of critical processes, including mucosal membrane permeability and virus interactions without requiring pathogenic viruses. Additionally, it is a powerful platform for screening active agents and developing antiviral drugs or preventive solutions, ensuring scalability, cost-efficiency and safety.
Current stage of development
19th of July of 2024 PCT receipt.